Critical Analysis: Bullfrog AI (NASDAQ:BFRG) and Fortrea (NASDAQ:FTRE)

Fortrea (NASDAQ:FTRE) and Bullfrog AI (NASDAQ:BFRG) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares Fortrea and Bullfrog AI”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72 billion	0.78	-$986.20 million	($0.91)	-24.52
Bullfrog AI	$120,000.00	85.28	-$6.50 million	($0.46)	-1.20

Bullfrog AI has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

1.0% of Bullfrog AI shares are held by institutional investors. 0.7% of Fortrea shares are held by company insiders. Comparatively, 14.7% of Bullfrog AI shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Fortrea has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -2.73, suggesting that its stock price is 373% less volatile than the S&P 500.

Profitability

This table compares Fortrea and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Bullfrog AI	N/A	-150.36%	-127.98%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Fortrea and Bullfrog AI, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	2	3	7	0	2.42
Bullfrog AI	1	1	0	0	1.50

Fortrea currently has a consensus price target of $22.60, indicating a potential upside of 1.28%. Given Fortrea’s stronger consensus rating and higher possible upside, analysts clearly believe Fortrea is more favorable than Bullfrog AI.

About Fortrea

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.